Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

A new study explores the reasons why tirzepatide, the once-weekly injection used to treat obesity and type 2 diabetes, is associated with greater weight loss in women than men.

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

"FDA has determined that the shortage of tirzepatide injection products, which first began in December 2022, is resolved," the agency said, per CNBC. "FDA continues to monitor supply and demand ...